drugset
Drugs / SOV2012-F1
last change May 2026 re-read 3 minutes ago

SOV2012-F1

also known as KYZATREX · testosterone undecanoate
Developed for
hypogonadism, male
Investigated by
Marius Pharmaceuticals · Syneos Health

Trials 1

today NCT04467697 · Ph 3
20192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT04467697 Sep 2018 → May 2020 hypogonadism, male Marius Pharmaceuticals Completed No outcome recorded

Press releases naming this drug 1 release

DateIssuerRelease
2026-05-05 Roxane Laboratories Hikma Pharmaceuticals and Marius Pharmaceuticals announce licensing agreement for KYZATREX® (testosterone undecanoate) CIII capsules in Canada hikma.com ↗

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as SOV2012-F1 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04467697 ↗
Known as KYZATREX “After titration, 87.8% of KYZATREX™ treated participants (worse-case scenario) and 96.1% of 90-day completers achieved eugonadal mean plasma T values.” PMID 38606384 ↗ Apr 2024
Known as testosterone undecanoate “Oral preparation of testosterone undecanoate (TU).” NCT04467697 ↗
Route Oral “Oral preparation of testosterone undecanoate (TU).” NCT04467697 ↗